The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a shifting landscape in healthcare technology, Citigroup has reiterated its 'Buy' rating for Abbott Laboratories, estimating the stock's fair value between $99 and $104. This bullish stance is supported by a 7.5% increase in continuous glucose monitoring (CGM) sales, which reached $2.00 billion in the first quarter. Furthermore, the company anticipates approximately $3 billion in incremental sales by 2026, following its strategic acquisition of Exact Sciences.
Sign in to access this content
Sign InThe valuation reflects optimism regarding Abbott's growth trajectory compared to its healthcare peers, particularly in the high-growth diagnostics segment. In the broader financial context, Citigroup (C) shares closed at $141.21 on June 15, 2026, while JPMorgan (JPM) stood at $336.03 on June 17, 2026, per market data. Analysts suggest that Abbott remains structurally undervalued relative to its long-term revenue potential from cancer diagnostics and diabetes care.
Traders should watch the current price action as ABT closed at $90.62 on June 16, 2026, suggesting potential upside toward the analyst price targets. Upcoming catalysts include the Michigan Consumer Sentiment index on June 12, which serves as a key indicator of US consumer health and spending capacity in the medical device sector.